BiotechTube

ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Reflux

Conditions

Gastroesophageal Reflux

Trial Timeline

Dec 1, 2008 → —

NCT ID
NCT00810485

About ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo

ADX10059 + ADX10059 + ADX10059 + ADX10059 Matching Placebo is a phase 2 stage product being developed by Addex Therapeutics for Gastroesophageal Reflux. The current trial status is completed. This product is registered under clinical trial identifier NCT00810485. Target conditions include Gastroesophageal Reflux.

What happened to similar drugs?

3 of 20 similar drugs in Gastroesophageal Reflux were approved

Approved (3) Terminated (1) Active (17)
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄E3810 + E3810 + PlaceboEisaiPhase 3
🔄Rabeprazole ER + RanitidineEisaiPhase 3
✅rabeprazole and pantoprazoleEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00810485Phase 2Completed
NCT00820105Phase 2Terminated

Competing Products

20 competing products in Gastroesophageal Reflux

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
FamotidineAstellas PharmaPhase 2/3
38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40
E3710 + E3710EisaiPhase 1
29
rabeprazole and pantoprazoleEisaiApproved
43
Rabeprazole 20 mgEisaiPhase 2
35
rabeprazole sodiumEisaiPhase 2
35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40